Mike Moradi

Mr. Moradi is a biotechnology executive and investor. He has co-founded several biopharmaceutical and nanotech companies, and several seed and venture capital funds. Mike is a venture partner for Cortado Ventures, an early-stage VC fund. Mike was previously a co-founder and CEO of a pharmaceutical company targeting ocular complications of diabetes, and specialty Contract Research Organization (eyeCRO), which was #264 fastest growing private company in the 2009 Inc. 500. He co-founded Nanopolaris (now Unidym), which was acquired in 2011 by a publicly traded South Korean company for $145M USD, and NanoSource, which was acquired by DuPont in 2002, largely considered the first major nanotechnology acquisition. Mike was a trustee for the $9B USD Oklahoma Pension Employees Retirement System (OPERS), and a member of the audit committee. He is an advisory board member for the Health Finance Institute, a regular attendee of the flagship TED conference, and the World Economic Forum in Davos. He holds a degree in biochemistry from the University of Oklahoma, with additional coursework from Oxford University’s Saïd Business School, the Harvard Kennedy School (also known as the John F. Kennedy School of Government at Harvard University), the Lee Kuan Yew School of Public Policy at the National University of Singapore, and the University of Cape Town’s Graduate School of Business. Mike was named to the World Economic Forum’s (WEF) 2017-2022 class of Young Global Leaders (YGL).